ALPHARMA INC
10-K/A, EX-27, 2000-11-15
PHARMACEUTICAL PREPARATIONS
Previous: ALPHARMA INC, 10-K/A, 2000-11-15
Next: ALPHARMA INC, 10-K/A, EX-23, 2000-11-15



<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          17,655
<SECURITIES>                                         0
<RECEIVABLES>                                  189,261
<ALLOWANCES>                                         0
<INVENTORY>                                    161,033
<CURRENT-ASSETS>                               381,872
<PP&E>                                         418,095
<DEPRECIATION>                                 173,682
<TOTAL-ASSETS>                               1,160,266
<CURRENT-LIABILITIES>                          164,276
<BONDS>                                        366,674
                                0
                                          0
<COMMON>                                         5,978
<OTHER-SE>                                     345,955
<TOTAL-LIABILITY-AND-EQUITY>                 1,160,266
<SALES>                                        732,443
<TOTAL-REVENUES>                               732,443
<CGS>                                          392,316
<TOTAL-COSTS>                                  392,316
<OTHER-EXPENSES>                               244,775
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              39,174
<INCOME-PRETAX>                                 57,628
<INCOME-TAX>                                    20,656
<INCOME-CONTINUING>                             36,972
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    36,972
<EPS-BASIC>                                       1.33
<EPS-DILUTED>                                     1.27


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission